1e
19
1
49
2
2
18
1b
1d
18
4a
5f
1d
2 29
1d
25
Larry J. Kricka, D.Phil., FACB, FRSC, C.Sci.
78
5f
Emeritus Professor CE of Pathology and Laboratory Medicine
7
78
Department: Pathology and Laboratory Medicine
4
1
b
1d
46
Contact information
5d
4
3
3
3
2
4
b
1f
5d
Department of Pathology and Laboratory Medicine
2e Hospital of University of Pennsylvania
35 3400 Spruce Street
Philadelphia, PA 19104
26
2e Hospital of University of Pennsylvania
35 3400 Spruce Street
Philadelphia, PA 19104
2e
Office: 215-662-6575
30
9b
12
30
13
Education:
21 a B.A. 1f (Chemistry w/honors) c
32 York University, York, UK, 1968.
21 c D.Phil. 16 (Chemistry) c
2f University of York, UK, 1971.
c
3
3
3
3
8b
Permanent link21 a B.A. 1f (Chemistry w/honors) c
32 York University, York, UK, 1968.
21 c D.Phil. 16 (Chemistry) c
2f University of York, UK, 1971.
c
2 29
21
1e
1d
24
5e
1a Chemiluminescence;
14 Immunoassay;
18 Bioluminescence;
13 Diagnostics.
26 29
27
Description of Research Expertise
25 Microminiaturization1a Chemiluminescence;
14 Immunoassay;
18 Bioluminescence;
13 Diagnostics.
26 29
23
ef Panaro NJ, Lou XJ, Fortina P, Kricka LJ, and Wilding P.: Surface effects on PCR reactions in multichip microfluidic platforms. Biomedical Microdevices 6: 75-80, 2004.
11c Lou JL, Panaro NJ, Wilding P, Fortina P, Kricka LJ: Mutation detection using ligase chain reaction in passivated silicon-glass microchips and microchip capillary electrophoresis. Biotechniques 37: 392-398, 2004.
d2 Gingeras T.R., Higuchi R., Kricka L.J., Lo D.Y.M.: Fifty years of molecular (DNA/RNA) diagnostics. Clinical Chemistry. 51: 661-667, 2005.
af Kricka L.J., Fortina P. : Future perspectives on nucleic acid testing. DNA and RNA testing for human disease monitoring 4e Lorincz A. (eds.). New York: Dekker, Page: 415-34, 2006.
fd Kricka LJ, Park JY, Reiprish A, Polsky TG, Nardiello MH.: The evolution of point-of-care testing. Point-of-Care. The Journal of Near-Patient Testing and Technology 14: 110-5, 2015.
e9 Kricka LJ.: Quality assurance for multiplexed assays – how can it be achieved? Scandinavian Journal of Clinical and Laboratory Investigation 76: S100-3, 2016.
cf Fortina P, London E, Park JY, Kricka LJ: Acute Myeloid Leukaemia: Methods and Protocols Methods in Molecular Biology. Springer, 2017.
f5 Kricka LJ, Polsky TG, Park JY, Fortina P. : The Future of Laboratory Medicine - a 2014 Perspective. Clinica Chimica Acta 438: 284-303, Jan 2015 Notes: Epub 2014, Sept 16.
100 Wang P, Kricka LJ. : Current and emerging trends in point of care testing technology and strategies for clinical validation and implementation. Clinical Chemistry 64: 1439-52, 2018.
a5 Kricka LJ, Heyner S. : Smartphones and semen analysis. Clinical Chemistry 64: 257-8, 2018.
fc Kricka LJ.: History of disruptions in laboratory medicine: what have we learned from predictions? Clinical Chemistry and Laboratory Medicine Page: 10.1515/cclm-2018-0518, 2018.
c6 Park JY, Kricka LJ.: One hundred years of clinical laboratory automation:1967-2067. Clinical Biochemistry 50: 639-44, 2017.
a8 Kricka LJ.: Photographic film, clinical chemistry and art. Clinical Chemistry 63: 1054-5, 2017.
bb Kricka LJ, Fortina P, Park JY.: Nanostructured luminescently-labeled nucleic acids. Luminescence 32: 132-41, 2017.
2c
7
1d
1f
Selected Publications
f8 Lou JL, Panaro NJ, Wilding P, Fortina P, Kricka LJ.: Increased amplification efficiency of microchip-based PCR by dynamic surface passivation. Biotechniques 36: 248-252, 2004.ef Panaro NJ, Lou XJ, Fortina P, Kricka LJ, and Wilding P.: Surface effects on PCR reactions in multichip microfluidic platforms. Biomedical Microdevices 6: 75-80, 2004.
11c Lou JL, Panaro NJ, Wilding P, Fortina P, Kricka LJ: Mutation detection using ligase chain reaction in passivated silicon-glass microchips and microchip capillary electrophoresis. Biotechniques 37: 392-398, 2004.
d2 Gingeras T.R., Higuchi R., Kricka L.J., Lo D.Y.M.: Fifty years of molecular (DNA/RNA) diagnostics. Clinical Chemistry. 51: 661-667, 2005.
af Kricka L.J., Fortina P. : Future perspectives on nucleic acid testing. DNA and RNA testing for human disease monitoring 4e Lorincz A. (eds.). New York: Dekker, Page: 415-34, 2006.
fd Kricka LJ, Park JY, Reiprish A, Polsky TG, Nardiello MH.: The evolution of point-of-care testing. Point-of-Care. The Journal of Near-Patient Testing and Technology 14: 110-5, 2015.
e9 Kricka LJ.: Quality assurance for multiplexed assays – how can it be achieved? Scandinavian Journal of Clinical and Laboratory Investigation 76: S100-3, 2016.
cf Fortina P, London E, Park JY, Kricka LJ: Acute Myeloid Leukaemia: Methods and Protocols Methods in Molecular Biology. Springer, 2017.
f5 Kricka LJ, Polsky TG, Park JY, Fortina P. : The Future of Laboratory Medicine - a 2014 Perspective. Clinica Chimica Acta 438: 284-303, Jan 2015 Notes: Epub 2014, Sept 16.
100 Wang P, Kricka LJ. : Current and emerging trends in point of care testing technology and strategies for clinical validation and implementation. Clinical Chemistry 64: 1439-52, 2018.
a5 Kricka LJ, Heyner S. : Smartphones and semen analysis. Clinical Chemistry 64: 257-8, 2018.
fc Kricka LJ.: History of disruptions in laboratory medicine: what have we learned from predictions? Clinical Chemistry and Laboratory Medicine Page: 10.1515/cclm-2018-0518, 2018.
c6 Park JY, Kricka LJ.: One hundred years of clinical laboratory automation:1967-2067. Clinical Biochemistry 50: 639-44, 2017.
a8 Kricka LJ.: Photographic film, clinical chemistry and art. Clinical Chemistry 63: 1054-5, 2017.
bb Kricka LJ, Fortina P, Park JY.: Nanostructured luminescently-labeled nucleic acids. Luminescence 32: 132-41, 2017.
2c